The National Medical Products Administration of China (NMPA) has approved the marketing of AbbVie’s direct-acting antiviral (DAA) Maviret (glecaprevir/pibrentasvir) on May 15, 2019. The hepatitis C drug with the best efficacy in the world has thus entered China, which is used to treat adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. With the advantage of curing hepatitis C in 8 weeks, Maviret was included in the second batch of clinically imperative overseas new drugs released by the NMPA upon “therapeutic advantages over marketed products”.
